PMID- 7745966
OWN - NLM
STAT- MEDLINE
DCOM- 19950615
LR  - 20131121
IS  - 0022-4804 (Print)
IS  - 0022-4804 (Linking)
VI  - 58
IP  - 5
DP  - 1995 May
TI  - Characterization of an oxidation-resistant tumor cell line and its sensitivity to 
      immune response and chemotherapy.
PG  - 526-35
AB  - Aerobic cells have several scavenger systems for protection from reactive oxygen 
      species (ROS). We developed an ROS-resistant variant of the human erythroleukemic 
      cell line K562 by culturing cells in glucose oxidase to produce hydrogen 
      peroxide. Testing the activity of the scavenger systems for ROS showed these 
      cells had a 25- to 28-fold increase in catalase activity. We therefore termed 
      this variant cell line K562-CAT. There was no similar increase in glutathione 
      content or activity of superoxide dismutase and glutathione peroxidase. To 
      determine what effect the increased catalase activity would have on the immune 
      response to these tumor cells, we compared K562 and K562-CAT sensitivity to tumor 
      necrosis factor-alpha (TNF alpha) activated polymorphonuclear neutrophil (PMN), 
      natural killer (NK), and lymphokine-activated killer (LAK) cells. K562-CAT showed 
      a significant increase in resistance to TNF alpha-activated PMN but not to NK or 
      LAK, confirming the role of ROS in the former but not the latter. We also tested 
      K562-CAT sensitivity to cisplatin and mitomycin C, agents known to involve ROS in 
      their cytotoxic mechanism. There was no increased resistance in K562-CAT compared 
      to parental K562, indicating that catalase is not involved in tumor cell 
      resistance to those drugs. Given the characteristics of its resistance to the 
      immune response, K562-CAT or a similar catalase-hyperexpressing cell line could 
      be useful in determining the significance of TNF alpha-activated PMN in antitumor 
      defenses.
FAU - Sauri, H
AU  - Sauri H
AD  - Division of Surgical Oncology, UCLA School of Medicine 90024-1782, USA.
FAU - Kim, A T
AU  - Kim AT
FAU - Shau, H
AU  - Shau H
LA  - eng
GR  - CA09010-18/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Surg Res
JT  - The Journal of surgical research
JID - 0376340
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - EC 1.11.1.6 (Catalase)
SB  - IM
MH  - Antibody Formation
MH  - Antineoplastic Agents/*pharmacology
MH  - Catalase/antagonists & inhibitors
MH  - Cytotoxicity, Immunologic
MH  - Drug Resistance
MH  - Humans
MH  - Hydrogen Peroxide/pharmacology
MH  - Killer Cells, Lymphokine-Activated/physiology
MH  - Killer Cells, Natural/physiology
MH  - Leukemia, Erythroblastic, Acute/*immunology/*metabolism/pathology
MH  - Neutrophils/drug effects/physiology
MH  - *Reactive Oxygen Species
MH  - Tumor Cells, Cultured
MH  - Tumor Necrosis Factor-alpha/pharmacology
EDAT- 1995/05/01 00:00
MHDA- 1995/05/01 00:01
CRDT- 1995/05/01 00:00
PHST- 1995/05/01 00:00 [pubmed]
PHST- 1995/05/01 00:01 [medline]
PHST- 1995/05/01 00:00 [entrez]
AID - S0022-4804(85)71083-9 [pii]
AID - 10.1006/jsre.1995.1083 [doi]
PST - ppublish
SO  - J Surg Res. 1995 May;58(5):526-35. doi: 10.1006/jsre.1995.1083.